-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutica.
com Market Analysis] Recently, the world's first new dual immune checkpoint inhibitor bispecific antibody drug developed by Kangfang Bio-Kaitany® (Cadonilimumab Injection) will be launched in Guangzh.
Held in Huangpu Distri.
It is understood that the new drug was independently developed by Kangfang Bio and is listed on the mark.
It can be used for the treatment of patients with recurrent or metastatic cervical cancer who have previously failed platinum-containing chemothera.
The new drug is China's first tumor immunotherapy double-antibody drug and the first tumor immunotherapy drug approved for the treatment of cervical canc.
Clinical research data shows that, compared with domestically approved therapies, the median overall survival of Ketanil in patients with recurrent or metastatic cervical cancer in the whole population is 151 months, which is 8 to 13 months longer than approved therapi.
of overall surviv.
In addition to the treatment in the field of cervical cancer, the research of Kaitany in the fields of gastric cancer, liver cancer, non-small cell lung cancer and nasopharyngeal cancer is also advancing rapid.
Coincidentally, on July 4, Hansoh Pharmaceutical also announced that the “Pilbociclib Capsules” developed by Jiangsu Hansoh Pharmaceutical Group .
, L.
, a subsidiary of the company, obtained a drug registration certificate issued by the State Drug Administration of Chi.
It is reported that this product is an anti-tumor drug, suitable for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer, and should be used in combination with aromatase inhibitors as menopau.
Post-Initial Endocrine Therapy in Female Patien.
In fact, in recent years, with the continuous growth of the tumor drug market, domestic pharmaceutical companies are scrambling to actively deploy in this fie.
At present, in addition to the successive listing of new drugs, the clinical research and development of innovative anti-tumor drugs in China is also progressing rapidly under the encouragement of innovative drug policies and centralized procurement polici.
Since July, a number of antitumor drugs have been approved for clinical tria.
For example, on July 12, Zhejiang Pharmaceutical issued an announcement stating that its subsidiary Zhejiang Xinma Bio-Pharmaceutical .
, L.
(hereinafter referred to as "Xinma Bio") received the approval and issuance of the recombinant humanized anti-CD70 monoclonal antibody for injection by the State Drug Administrati.
-AS269 conjugate (ARX305) "Drug Clinical Trial Approval Notice", agreeing to carry out clinical trials of this product as a single drug in patients with advanced tumo.
Recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for injection (ARX305) is a new generation of monoclonal antibody conjugates jointly developed by Xinma Bio and Ambrx in the United States on October 22, 201 Combination drugs for the treatment of CD70-expressing advanced tumo.
On July 11, Hengrui Medicine issued two drug clinical trials approval notices, namely SHR-1701 injection combined with almetinib and other innovative drugs in the treatment of EGFR-mutated recurrent or advanced non-small cell lung cancer open, multi-center .
/Phase II clinical study, HRS-1167 tablet to carry out clinical trials of advanced solid tumo.
On July 5, Fosun Pharma issued an announcement that Shanghai Fosun, a holding subsidiary, received the approval from the State Food and Drug Administration for the approval of FS-1502 (ie, the recombinant HER2 humanized monoclonal antibody monomethyl auristatin F coupling agent for injectio.
) in combination with slulimumab and/or chemotherapy for the treatment of HER2-expressing advanced gastric cancer patients for clinical tria.
Industry analysts believe that the field of anti-tumor drugs, as a hot disease field, with the continuous efforts of pharmaceutical companies, will gradually enter the harvest peri.
However, it should be noted that with the normalization of centralized drug procurement and medical insurance negotiations, the market exclusive rights of anti-tumor drugs will become shorter and short.
Even exclusive new drugs are difficult to stand on for a long time, so the competition of enterprises in this field will become more intense in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
com Market Analysis] Recently, the world's first new dual immune checkpoint inhibitor bispecific antibody drug developed by Kangfang Bio-Kaitany® (Cadonilimumab Injection) will be launched in Guangzh.
Held in Huangpu Distri.
It is understood that the new drug was independently developed by Kangfang Bio and is listed on the mark.
It can be used for the treatment of patients with recurrent or metastatic cervical cancer who have previously failed platinum-containing chemothera.
The new drug is China's first tumor immunotherapy double-antibody drug and the first tumor immunotherapy drug approved for the treatment of cervical canc.
Clinical research data shows that, compared with domestically approved therapies, the median overall survival of Ketanil in patients with recurrent or metastatic cervical cancer in the whole population is 151 months, which is 8 to 13 months longer than approved therapi.
of overall surviv.
In addition to the treatment in the field of cervical cancer, the research of Kaitany in the fields of gastric cancer, liver cancer, non-small cell lung cancer and nasopharyngeal cancer is also advancing rapid.
Coincidentally, on July 4, Hansoh Pharmaceutical also announced that the “Pilbociclib Capsules” developed by Jiangsu Hansoh Pharmaceutical Group .
, L.
, a subsidiary of the company, obtained a drug registration certificate issued by the State Drug Administration of Chi.
It is reported that this product is an anti-tumor drug, suitable for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer, and should be used in combination with aromatase inhibitors as menopau.
Post-Initial Endocrine Therapy in Female Patien.
In fact, in recent years, with the continuous growth of the tumor drug market, domestic pharmaceutical companies are scrambling to actively deploy in this fie.
At present, in addition to the successive listing of new drugs, the clinical research and development of innovative anti-tumor drugs in China is also progressing rapidly under the encouragement of innovative drug policies and centralized procurement polici.
Since July, a number of antitumor drugs have been approved for clinical tria.
For example, on July 12, Zhejiang Pharmaceutical issued an announcement stating that its subsidiary Zhejiang Xinma Bio-Pharmaceutical .
, L.
(hereinafter referred to as "Xinma Bio") received the approval and issuance of the recombinant humanized anti-CD70 monoclonal antibody for injection by the State Drug Administrati.
-AS269 conjugate (ARX305) "Drug Clinical Trial Approval Notice", agreeing to carry out clinical trials of this product as a single drug in patients with advanced tumo.
Recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for injection (ARX305) is a new generation of monoclonal antibody conjugates jointly developed by Xinma Bio and Ambrx in the United States on October 22, 201 Combination drugs for the treatment of CD70-expressing advanced tumo.
On July 11, Hengrui Medicine issued two drug clinical trials approval notices, namely SHR-1701 injection combined with almetinib and other innovative drugs in the treatment of EGFR-mutated recurrent or advanced non-small cell lung cancer open, multi-center .
/Phase II clinical study, HRS-1167 tablet to carry out clinical trials of advanced solid tumo.
On July 5, Fosun Pharma issued an announcement that Shanghai Fosun, a holding subsidiary, received the approval from the State Food and Drug Administration for the approval of FS-1502 (ie, the recombinant HER2 humanized monoclonal antibody monomethyl auristatin F coupling agent for injectio.
) in combination with slulimumab and/or chemotherapy for the treatment of HER2-expressing advanced gastric cancer patients for clinical tria.
Industry analysts believe that the field of anti-tumor drugs, as a hot disease field, with the continuous efforts of pharmaceutical companies, will gradually enter the harvest peri.
However, it should be noted that with the normalization of centralized drug procurement and medical insurance negotiations, the market exclusive rights of anti-tumor drugs will become shorter and short.
Even exclusive new drugs are difficult to stand on for a long time, so the competition of enterprises in this field will become more intense in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
